Apricus Biosciences Inc. (NASDAQ:APRI) Receives $2.23 Consensus Target Price from Analysts
Shares of Apricus Biosciences Inc. (NASDAQ:APRI) have been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the stock. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $2.23.
Separately, Zacks Investment Research downgraded shares of Apricus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th.
Shares of Apricus Biosciences (NASDAQ:APRI) opened at 0.355 on Tuesday. Apricus Biosciences has a 1-year low of $0.28 and a 1-year high of $1.66. The company’s market capitalization is $23.55 million. The company’s 50 day moving average is $0.36 and its 200-day moving average is $0.44.
Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. During the same quarter last year, the company earned ($0.10) earnings per share. On average, equities research analysts forecast that Apricus Biosciences will post ($0.17) EPS for the current year.
An institutional investor recently raised its position in Apricus Biosciences stock. Vanguard Group Inc. boosted its position in Apricus Biosciences Inc. (NASDAQ:APRI) by 0.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,511,841 shares of the company’s stock after buying an additional 9,786 shares during the period. Vanguard Group Inc. owned approximately 2.44% of Apricus Biosciences worth $604,000 as of its most recent SEC filing. 23.83% of the stock is currently owned by institutional investors and hedge funds.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Stock Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related stocks with our FREE daily email newsletter.